Intraventricular CARv3 TEAM E T Cells in Recurrent Glioblastoma

This first in human phase 1 study evaluated CARv3 TEAM E T cells engineered to target EGFRvIII and secrete T cell engaging antibody molecules against wild type EGFR in three patients with recurrent glioblastoma. A single intraventricular infusion led to rapid radiographic tumor regression in all participants, with one showing durable response beyond 150 days. No dose limiting toxicities or grade ≥4 adverse events occurred. Correlative analyses confirmed EGFRvIII and EGFR transcript clearance in cerebrospinal fluid and peripheral blood. The study demonstrates feasibility, safety, and early signs of efficacy for dual targeting CAR T cell therapy in glioblastoma.

This first in human phase 1 study evaluated CARv3 TEAM E T cells engineered to target EGFRvIII and secrete T cell engaging antibody molecules against wild type EGFR in three patients with recurrent glioblastoma. A single intraventricular infusion led to rapid radiographic tumor regression in all participants, with one showing durable response beyond 150 days. No dose limiting toxicities or grade ≥4 adverse events occurred. Correlative analyses confirmed EGFRvIII and EGFR transcript clearance in cerebrospinal fluid and peripheral blood. The study demonstrates feasibility, safety, and early signs of efficacy for dual targeting CAR T cell therapy in glioblastoma.